Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Bayer Zydus Pharma to...

    Bayer Zydus Pharma to continue to invest in new medicines

    GarimaWritten by Garima Published On 2019-03-31T10:00:54+05:30  |  Updated On 31 March 2019 10:00 AM IST
    Bayer Zydus Pharma to continue to invest in new medicines

    The strong performance for multiple years speaks of the growing demand for its medicines to patients battling serious ailments such as cardiovascular diseases, cancer, and eye diseases related to ageing and diabetes.


    Singapore: The Indian pharmaceutical sector is growing impressively and German pharma major Bayer will continue to invest in the country for new drugs, a top company official has said.


    The company is satisfied with the performance of its equal joint venture (JV) with Zydus Cadila, the official has noted. The JV is called Bayer Zydus Pharma.


    "The Indian pharma market is growing at a very impressive rate and so has our business. We want to continue bringing most of our new medicines to India," Bayer Asia Pacific Senior Vice-President Claus Zieler told here earlier this week without specifying the growth numbers for the company or for the market.


    Asked about how he assesses the India operations, Zieler said, "We've been in a joint venture with Zydus Cadila since 2011 and it has been a successful collaboration. We're pleased with that and we are continuing to invest together with Zydus in India".


    He did not quantify how much the proposed investments would be or a timeline, though. The strong performance for multiple years speaks of the growing demand for its drugs to patients battling serious ailments such as cardiovascular diseases, cancer, and eye diseases related to ageing and diabetes.


    "We'll continue to bring new and better drugs to India and build more collaborations with external partners," he said.


    Zieler said for cancer, precision medicines will hold a greater promise as it can ensure more targeted therapies and better outcomes. Despite progress in cancer survivals, there is still a higher medical need in this area, Zieler said adding that Asia accounts for half of the world's cancer burden and it is estimated that cancer cases in the continent will reach 10.6 million by 2030.


    Bayer India's joint venture Bayer Zydus Pharma operates in key segments of the domestic drug market with a focus on women's health, metabolic disorders, diagnostic imaging, cardiovascular diseases, anti-diabetic treatment and oncology.


    Bayer's Asia-Pacific Head for Medical Affairs Chuan Kit Foo said they are working to address the healthcare burden in the region by bringing in new and better treatments to patients.


    "By involving Asia-Pacific patients in our clinical development activities, we can provide patients with earlier access to our innovative medicines," he said.


    Bayer saw a 7.3 per cent growth in Asia-Pacific sales to over 5.2 billion euros in 2018 led by strong growth in Australia, South Korea, Taiwan, China, the Philippines and Indonesia, and it eyeing a topline growth of about 4 per cent globally in 2019.


    The company has also tied up with the National University of Singapore to launch an initiative to drive healthcare innovations to help prevent strokes and heart attacks.


    Also Read: Zydus Cadila gets USFDA nod for Ambrisentan tablets to treat high BP

    ageingBayerBayer Zydus PharmaCadila HealthcarecancerCardiovascular diseasesdiabeteseye diseaseshealthHealthcareHealthcare NewsIndiaindian pharmaindian pharma newsIndian pharmaceutical sectormedicalmedicinemedicinesnew drugspharmapharma newspharma news indiazydusZydus Cadila
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok